On December 27, 2023, Applied Molecular Transport Inc. (?AMTI?), completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023 (the ?Merger Agreement?), by and among Cyclo Therapeutics, Inc. (?Cyclo?), Cameo Merger Sub, Inc. and wholly owned subsidiary of Cyclo (?Merger Sub?) and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the ?Merger?). As of the Effective Time: Shawn Cross, a former director of AMTI, was appointed to the board of directors of Cyclo.